Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Bluejay Diagnostics (NASDAQ: BJDX) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bluejay Diagnostics (NASDAQ: BJDX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte Palace Hotel, New York City. CEO Neil Dey and CFO Kenneth Fisher will present on September 13 at 10:30 AM ET. The management team will also engage in one-on-one meetings with investors. Bluejay focuses on rapid, cost-effective diagnostic testing, with its first candidate, an IL-6 Test for sepsis triage, promising results in about 20 minutes. For further details, visit bluejaydx.com.
Details
News Market Reaction – BJDX
The recorded move for BJDX in the trading session of this news was +2.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Hotel in New York City.
H.C. Wainwright 24th Annual Global Investment Conference
| Date: | Tuesday, September 13, 2022 |
| Time: | 10:30 AM ET |
The Bluejay management team will also participate in one-on-one meetings during the event. Investors interested in meeting with Bluejay at the conference should contact their H.C. Wainwright representative.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Investor Contact:
Alexandra Schuman
LifeSci Advisors
alex@lifesciadvisors.com
t: 646-876-3647
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.